A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs MVA CMV (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- 08 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 08 Jun 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Apr 2018.
- 16 Mar 2017 According to a Fortress Biotech media release, this trial is expected to be fully enrolled by the second half of 2017.